- Home
- VCEL
VCEL
Vericel Corporation
as 05-15-2025 4:00pm EST
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
| Founded: | 1989 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 2.1B | IPO Year: | 1997 |
| Target Price: | $61.75 | AVG Volume (30 days): | 547.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.05 | EPS Growth: | 521.85 |
| 52 Week Low/High: | $37.39 - $63.00 | Next Earning Date: | 05-08-2025 |
| Revenue: | $238,541,000 | Revenue Growth: | 14.80% |
| Revenue Growth (this year): | 23.23% | Revenue Growth (next year): | 24.41% |
Stock Insider Trading Activity of Vericel Corporation (VCEL)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| MCLAUGHLIN KEVIN F | VCEL | Director | May 7 '25 | Sell | $39.98 | 7,000 | $279,860.00 | 15,100 | |
| Colangelo Dominick | VCEL | President and CEO | Apr 9 '25 | Sell | $41.50 | 49,700 | $2,062,550.00 | 260,354 | |
| Colangelo Dominick | VCEL | President and CEO | Mar 12 '25 | Sell | $46.05 | 53,183 | $2,448,810.97 | 260,354 | |
| Halpin Michael | VCEL | Chief Operating Officer | Mar 3 '25 | Sell | $49.52 | 10,000 | $495,200.00 | 15,539 | |
| Hopper Jonathan Mark | VCEL | Chief Medical Officer | Mar 3 '25 | Sell | $49.53 | 10,000 | $495,300.00 | 66,101 | |
| Mara Joseph Anthony Jr | VCEL | Chief Financial Officer | Mar 3 '25 | Sell | $49.53 | 9,000 | $445,770.00 | 13,967 | |
| Hagen Heidi | VCEL | Director | Mar 3 '25 | Sell | $49.53 | 9,000 | $445,770.00 | 28,650 | |
| Flynn Sean C. | VCEL | Chief Legal Officer | Feb 24 '25 | Sell | $52.07 | 1,669 | $86,904.83 | 756 | |
| SIEGAL JONATHAN | VCEL | Principal Accounting Officer | Feb 24 '25 | Sell | $52.07 | 1,137 | $59,203.59 | 1,206 | |
| Flynn Sean C. | VCEL | Chief Legal Officer | Feb 20 '25 | Sell | $57.32 | 3,835 | $219,822.20 | 756 |
Latest Vericel Corporation News
VCEL Breaking Stock News: Dive into VCEL Ticker-Specific Updates for Smart Investing
Argus Research
2 days ago
VCEL: Raising target price to $48.00
Simply Wall St.
5 days ago
Vericel First Quarter 2025 Earnings: Misses Expectations
MT Newswires
6 days ago
Truist Securities Adjusts Price Target on Vericel to $52 From $51, Maintains Buy Rating
GuruFocus.com
7 days ago
Vericel Corp (VCEL) Q1 2025 Earnings Call Highlights: Record Revenue and Strategic Growth ...
MT Newswires
7 days ago
Vericel's Q1 Loss Widens, Revenue Rises; 2025 Revenue Growth Outlook Reiterated
Zacks
7 days ago
Vericel Corporation (VCEL) Reports Q1 Loss, Misses Revenue Estimates
Insider Monkey
7 days ago
Vericel Corporation (VCEL): Among Stocks with Insanely High PE Ratios Insiders Are Selling
GlobeNewswire
7 days ago
Vericel Reports First Quarter 2025 Financial Results and Raises Full-Year Profitability Guidance
Compare VCEL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VCEL Vericel Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.